POU2F3-Expressing Small Cell Lung Carcinoma and Large Cell Neuroendocrine Carcinoma Show Morphologic and Phenotypic Overlap

POU2F3 beyond thymic carcinomas: expression across the spectrum of thymomas hints to medullary differentiation in type A thymoma

(2022) Yosuke Yamada et al.   VIRCHOWS ARCHIV

Expression patterns and prognostic relevance of subtype‐specific transcription factors in surgically resected small‐cell lung cancer: an international multicenter study

(2022) Zsolt Megyesfalvi et al.   JOURNAL OF PATHOLOGY

POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC

(2022) Marina K. Baine et al.   Journal of Thoracic Oncology

Molecular Classification of Extrapulmonary Neuroendocrine Carcinomas With Emphasis on POU2F3-positive Tuft Cell Carcinoma

(2022) Jiwon Koh et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Tuft cell-like carcinomas: novel cancer subsets present in multiple organs sharing a unique gene expression signature

(2022) Yosuke Yamada et al.   BRITISH JOURNAL OF CANCER

Determining Whether YAP1 and POU2F3 Are Antineuroendocrine Factors

(2022) Ryota Matsuoka et al.   Journal of Thoracic Oncology

Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities

(2022) Yosuke Yamada et al.   Cell Death & Disease

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

(2021) Carl M. Gay et al.   CANCER CELL

A Tuft Cell–Like Signature Is Highly Prevalent in Thymic Squamous Cell Carcinoma and Delineates New Molecular Subsets Among the Major Lung Cancer Histotypes

(2021) Yosuke Yamada et al.   Journal of Thoracic Oncology

Seven key hub genes identified by gene co-expression network in cutaneous squamous cell carcinoma

(2021) Huizhen Chen et al.   BMC CANCER

Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer

(2021) Nicholas J. Brady et al.   Nature Communications

Pulmonary neuroendocrine carcinomas in situ : do they exist?

(2021) Yale Rosen   HISTOPATHOLOGY

New Approaches to SCLC Therapy: From the Laboratory to the Clinic

(2020) John T. Poirier et al.   Journal of Thoracic Oncology

Insulinoma‐associated protein 1 is a prognostic biomarker in pulmonary high‐grade neuroendocrine carcinoma

(2020) Kazuhiro Minami et al.   JOURNAL OF SURGICAL ONCOLOGY

Dissecting the cellular specificity of smoking effects and reconstructing lineages in the human airway epithelium

(2020) Katherine C. Goldfarbmuren et al.   Nature Communications

Small Cell Lung Carcinoma Subtypes Defined by ASCL1, NEUROD1, POU2F3 and YAP1: Comprehensive Immunohistochemical and Histopathologic Characterization

(2020) Marina K. Baine et al.   Journal of Thoracic Oncology

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

(2020) Jonathan W Goldman et al.   LANCET ONCOLOGY

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

(2019) Taofeek K. Owonikoko et al.   Journal of Thoracic Oncology

Neuroendocrine marker staining pattern categorization of small‐sized pulmonary large cell neuroendocrine carcinoma

(2019) Kazuhiro Minami et al.   Thoracic Cancer

POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer

(2018) Yu-Han Huang et al.   GENES & DEVELOPMENT

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

(2018) M. Catherine Pietanza et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tuft Cells—Systemically Dispersed Sensory Epithelia Integrating Immune and Neural Circuitry

(2018) Claire E. O'Leary et al.   Annual Review of Immunology

Loss ofYAP1defines neuroendocrine differentiation of lung tumors

(2016) Takeshi Ito et al.   CANCER SCIENCE

High-Grade Neuroendocrine Carcinoma with Bronchial Intraepithelial Tumor Spread

(2015) Hideaki Kojima et al.   Journal of Thoracic Oncology

Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells

(2015) Haiying Cheng et al.   Oncotarget

Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer

(2010) Yang Wang et al.   CANCER SCIENCE